STX-478
mutant-selective, allosteric PI3Ka inhibitor Ph. I/II for breast cancer and other solid tumors from affinity selection mass spectrometry (ASMS) screen Cancer Discov., August 2023 Scorpion Therapeutics, Boston, MA
10 minute read
Oct. 2, 2023
A Next-Generation Mutant-Selective PI3Kα Allosteric Inhibitor with a Potentially Improved Safety Profile